Suhler EB, et al. - The safety and effectiveness of adalimumab were assessed in the cases having noninfectious intermediate, posterior, or panuveitis. A likelihood of achieving quiescence, improving visual acuity and reducing the daily uveitis-related systemic corticosteroid use was seen in patients with active uveitis at study entry who received adalimumab therapy. Quiescence was sustained without a systemic corticosteroid dose increase by the patients with inactive uveitis at study entry. Findings did not reveal any new safety signals.